Citation Tools
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers